Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Background To reduce the risk of thromboembolic complications, clinical guidelines
recommend anticoagulation treatment for almost all atrial fibrillation (AF) patients. Although …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Background and objective Non-valvular atrial fibrillation (NVAF) increases the risk of
systemic thromboembolic events; therefore, anticoagulant treatment with vitamin K …

ABSTRACT BACKGROUND: Apixaban, an oral anticoagulant for stroke and systemic
embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in …

Background Non-vitamin K antagonist oral anticoagulants (NOACs), including apixaban, are
recommended for prevention of stroke and systemic embolism in non-valvular atrial …

Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …